Team

Jonas Ekblom
Jonas Ekblom
President & Chief Executive Officer (CEO)

Born: 1965.

Jonas has worked over 25 years in the Life Science sector. He is an assistant professor in pharmacology at Uppsala University, he has a B.Sci. in Chemistry from University of Stockholm, and a Ph.D. in Experimental Neurology from Uppsala University, post-doctoral studies at University of Southern California, School of Pharmacy in LA. He has also received education in strategic planning and business management. Jonas has previously held executive roles in biotech companies in Sweden, US and Switzerland. Most recently, he served as CEO for the Swiss biotech BOWS Pharmaceuticals SA, and prior held senior and executive positions in Pharmacia, Biovitrum, Sequenom and Invitrogen. Jonas has worked as CEO in the group since 2010. Between 2015 and 2017 he was consultant CEO. He was employed as president and CEO for the group from May 1, 2017.

Other Assignments: Chairman of Axelar AB and EffRx Pharmaceuticals SA as well as principal of his own consultancy practice Edge of the World Strategies Corporation.
Share Holding in Promore Pharma: No current holding.

Jenni Björnulfson
Jenni Björnulfson
Chief Financial Officer (CFO)

Born: 1971.

Jenni has extensive professional experience from the financial markets, having worked with corporate finance for over ten years with Handelsbanken Markets and Alfred Berg Fondkommission/ABM AMRO. Jenni has also worked three years as a stock analytics at Standard & Poor’s and at ABG Sundal Collier. She has been business area manager at Global Health Partners AB. Jenni has a training in economy from Stockholm School of Economics, and has served as CFO of Promore Pharma since 2016.

Other Assignments
: Jenni is a board director in Hemcheck Sweden AB as well as principal of her own consultancy practice The C Story AB.
Share Holding in Promore Pharma: 1,500 shares.

Margit Mahlapuu
Margit Mahlapuu
Chief Scientific Officer (CSO)

Born: 1972.

Margit has over 15 years of experience in pharmaceutical research and development. She has had assignments at companies such as AstraZeneca, Arexis, and Swedish Orphan Biovitrum. Margit holds an associate professorship in Molecular Medicine at Sahlgrenska Academy, Sweden. She has a Ph.D. in Molecular and Cellular Biology from the University of Gothenburg. Margit joined the company in 2007 and has since then been responsible for regulatory affairs strategy and clinical development.

Other Assignments: Margit is a director of the board in Sixera AB, she is CEO of to IP holding companies ScandiCure AB and Alexera AB and she is CEO and chairman of her own consultancy practice Arexela AB, an intellectual property holding company.
Share Holding in Promore Pharma: No current holding.

Ulrika Wennberg
Ulrika Wennberg
Chief Operating Officer (COO)

Born: 1970.

Ulrika has more than 20 years of experience in project management, management consulting and business leadership in biotech, IT and media. She was previously CEO of Axelar AB and CFO and CEO of Jederström Pharmaceuticals. Ulrika has a B.Sc in Business Administration from Lund University and a Master in Environmental Management from European Association for Environmental Management Education (EAEME). Ulrika started within the group in 2009.

Other Assignments: Ulrika is civil accountant in SRV Återvinning AB, Söderenergi Aktiebolag and Söderenergi Kraftvärme Aktiebolag. She is deputy civil accountant in Huge Bostäder AB, Huddinge Samhällsfastigheter AB, Södertörns Fjärrvärme AB and Södertörns Energi AB.
Share Holding in Promore Pharma: 500 shares.

Alexandra Liverts
Alexandra Liverts
Office Manager

Born: 1980.

Alexandra has more than 10 years of professional experience from research administration including roles as administration officer, program coordinator and project manager within the Israeli academic system. Alexandra has a B.A. in Health Systems Management from Ben-Gurion University of the Negev and a Master in Occupational Health from Tel Aviv University. Alexandra is Office Manager and Finance Assistant in Promore Pharma since 2017.

Share Holding in Promore Pharma
: No current holding.

Holdings as of March 29, 2019.